NovaBridge Biosciences
NBPFigures shown here come from public SEC filings. Dates beside each section show the available history.
How NovaBridge Biosciences Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: NovaBridge Biosciences — 20-F filed Apr 7, 2026
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 10 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 30, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| AIHC Capital Management Ltd | 2026-03-31 | 2,262,933 | $5.57M | SEC filing |
| GEODE CAPITAL MANAGEMENT, LLC | 2026-03-31 | 68,849 | $169K | SEC filing |
| HRT FINANCIAL LP | 2026-03-31 | 107,524 | Not shown | SEC filing |
| Schonfeld Strategic Advisors LLC | 2026-03-31 | 35,414 | $87.1K | SEC filing |
| Eurizon Capital SGR S.p.A. | 2026-03-31 | 1 | $2 | SEC filing |
| DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. | 2026-03-31 | 80,400 | $198K | SEC filing |
| JANUS HENDERSON GROUP PLC | 2026-03-31 | 6,032,650 | $14.8M | SEC filing |
| Mirae Asset Global Investments Co., Ltd. | 2026-03-31 | 5,855 | $14.4K | SEC filing |
| SBI Securities Co., Ltd. | 2026-03-31 | 225 | $554 | SEC filing |
| Candriam S.C.A. | 2026-03-31 | 1,132,563 | $2.79M | SEC filing |
| Vermillion Wealth Management, Inc. | 2026-03-31 | 200 | $492 | SEC filing |
| CITIGROUP INC | 2026-03-31 | 3,187 | $7.84K | SEC filing |
| MORGAN STANLEY | 2026-03-31 | 3,838,198 | $9.44M | SEC filing |
| BlackRock, Inc. | 2026-03-31 | 627,496 | $1.54M | SEC filing |
| Invesco Ltd. | 2026-03-31 | 28,161 | $69.3K | SEC filing |
| PNC FINANCIAL SERVICES GROUP, INC. | 2026-03-31 | 2,000 | $4.92K | SEC filing |
| Woodline Partners LP | 2026-03-31 | 700,000 | $1.72M | SEC filing |
| UBS Group AG | 2026-03-31 | 63,541 | $156K | SEC filing |
| GOLDMAN SACHS GROUP INC | 2026-03-31 | 112,463 | $277K | SEC filing |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2026-03-31 | 1,000,000 | $2.46M | SEC filing |
- Each value is checked against NovaBridge Biosciences's share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the filed value is about 1,000 times too small for the share count at NovaBridge Biosciences's share price.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- STATE STREET CORP: 359,878 shares reported 2025-12-31; 370,107 shares reported 2026-03-31.
- Freestone Capital Holdings, LLC: 10,000 shares reported 2025-12-31; 10,000 shares reported 2026-03-31.
- Squarepoint Ops LLC: 34,322 shares reported 2025-12-31; 23,807 shares reported 2026-03-31.
- ROYAL BANK OF CANADA: 6,360 shares reported 2025-12-31; 99 shares reported 2026-03-31.
- Tower Research Capital LLC (TRC): 1,765 shares reported 2025-12-31; 3,241 shares reported 2026-03-31.
- JPMORGAN CHASE & CO: 131,830 shares reported 2025-12-31; 57,489 shares reported 2026-03-31.
- GF FUND MANAGEMENT CO. LTD.: 2,042 shares reported 2025-12-31; 2,321 shares reported 2026-03-31.
- RHUMBLINE ADVISERS: 33 shares reported 2025-12-31; 33 shares reported 2026-03-31.
- SUSQUEHANNA INTERNATIONAL GROUP, LLP: 47,479 shares reported 2025-12-31; 12,817 shares reported 2026-03-31.
- Caitong International Asset Management Co., Ltd: 528 shares reported 2025-12-31; 25,982 shares reported 2026-03-31.
- DIMENSIONAL FUND ADVISORS LP: 148,452 shares reported 2025-12-31; 146,322 shares reported 2026-03-31.
- HHLR ADVISORS, LTD.: 5,980,568 shares reported 2025-12-31; 5,980,568 shares reported 2026-03-31.
Showing the 12 most recent filer reports.
25 filers have only one report here.
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-18 | Dennis Phillip Andrew · Chief Medical Officer | Ordinary Shares | S — Open market or private sale | −8,494 | 0.66 | SEC filing |
| 2026-06-01 | Xu Cong Claire · SVP, Clinical Development | Ordinary Shares | S — Open market or private sale | −3,494 | 3.94 | SEC filing |
| 2026-05-14 | Cao Sean Wuxiong · See Remarks | Ordinary Shares | S — Open market or private sale | −21,399 | 1.99 | SEC filing |
| 2026-04-24 | Hagler Mark Arnold · See Remarks | Ordinary Shares | P — Open market or private purchase | +230,000 | 2.51 | SEC filing |
Showing 4 of 4 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-29 | Fu Wei · Director | 2025 Employee Share Option (right to buy) | A — Grant, award, or other acquisition | +1,087,720 | SEC filing |
| 2026-06-29 | Fu Wei · Director | 2025 Employee Share Option (right to buy) | A — Grant, award, or other acquisition | +725,140 | SEC filing |
| 2026-06-29 | Fu Wei · Director | Restricted Share Units | A — Grant, award, or other acquisition | +1,010,100 | SEC filing |
| 2026-06-22 | Cao Sean Wuxiong · Chief Bus. Development Officer | 2025 Employee Share Option (right to buy) | A — Grant, award, or other acquisition | +181,290 | SEC filing |
| 2026-06-22 | Cao Sean Wuxiong · Chief Bus. Development Officer | Restricted Share Units | A — Grant, award, or other acquisition | +181,280 | SEC filing |
| 2026-06-17 | Dennis Phillip Andrew · Chief Medical Officer | Restricted Share Units | M — Exercise or conversion of derivative security | −10,302 | SEC filing |
| 2026-06-17 | Dennis Phillip Andrew · Chief Medical Officer | Ordinary Shares | M — Exercise or conversion of derivative security | +23,695 | SEC filing |
| 2026-05-30 | Xu Cong Claire · SVP, Clinical Development | Restricted Share Units | M — Exercise or conversion of derivative security | −4,079 | SEC filing |
Showing 8 of 9 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.